用于治疗肝缺血再灌注损伤的纳米治疗学,Small

当前位置： X-MOL 学术 › Small › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

用于治疗肝缺血再灌注损伤的纳米治疗学
Small ( IF 13.0 ) Pub Date : 2021-04-14 , DOI: 10.1002/smll.202007727
Yu Guan ₁ , Weifeng Yao ₁ , Ke Yi ₁ , Chunxiong Zheng _{1,

2} , Shixian Lv ₃ , Yu Tao _{1,

2} , Ziqing Hei ₁ , Mingqiang Li _{1,

2}

Affiliation

肝缺血再灌注损伤（IRI），其中氧气供应不足，然后再灌注导致疾病组织中的炎症网络和氧化应激导致细胞死亡，总是发生在肝移植和切片之后。尽管药物治疗有利于预防或保护肝脏免受实验性 IRI 的影响，但由于不理解复杂的 IRI 诱导的信号事件以及血液循环时间短、溶解性差和严重的副反应，在临床应用中对患者的益处很少取得成功大多数抗氧化剂和抗炎药。纳米材料可以在所需的肝脏 IRI 区域实现造影剂和治疗药物的靶向递送和可控释放，以提高成像灵敏度和改善治疗效果，正在成为肝脏 IRI 诊断和治疗的新替代方法。本综述总结了纳米技术在肝脏 IRI 治疗中的应用，包括纳米材料辅助肝脏 IRI 诊断、纳米颗粒系统介导的活性氧诱导的组织损伤缓解，以及基于纳米颗粒的靶向给药系统缓解肝脏 IRI。 IRI 相关炎症。还讨论了这些用于肝脏 IRI 治疗的纳米化策略的当前挑战和未来前景。纳米颗粒系统介导的活性氧诱导的组织损伤缓解，以及用于缓解 IRI 相关炎症的基于纳米颗粒的靶向药物递送系统。还讨论了这些用于肝脏 IRI 治疗的纳米化策略的当前挑战和未来前景。纳米颗粒系统介导的活性氧诱导的组织损伤缓解，以及用于缓解 IRI 相关炎症的基于纳米颗粒的靶向药物递送系统。还讨论了这些用于肝脏 IRI 治疗的纳米化策略的当前挑战和未来前景。

"点击查看英文标题和摘要"

Nanotheranostics for the Management of Hepatic Ischemia-Reperfusion Injury

Hepatic ischemia-reperfusion injury (IRI), in which an insufficient oxygen supply followed by reperfusion leads to an inflammatory network and oxidative stress in disease tissue to cause cell death, always occurs after liver transplantations and sections. Although pharmacological treatments favorably prevent or protect the liver against experimental IRI, there have been few successes in clinical applications for patient benefits because of the incomprehension of complicated IRI-induced signaling events as well as short blood circulation time, poor solubility, and severe side reactions of most antioxidants and anti-inflammatory drugs. Nanomaterials can achieve targeted delivery and controllable release of contrast agents and therapeutic drugs in desired hepatic IRI regions for enhanced imaging sensitivity and improved therapeutic effects, emerging as novel alternative approaches for hepatic IRI diagnosis and therapy. In this review, the application of nanotechnology is summarized in the management of hepatic IRI, including nanomaterial-assisted hepatic IRI diagnosis, nanoparticulate systems-mediated remission of reactive oxygen species-induced tissue injury, and nanoparticle-based targeted drug delivery systems for the alleviation of IRI-related inflammation. The current challenges and future perspectives of these nanoenabled strategies for hepatic IRI treatment are also discussed.

更新日期：2021-06-10

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南